Skip to main content

Myriad, DaVita Team on Protein Marker Research

NEW YORK (GenomeWeb News) – Myriad Genetics today said that its Myriad RBM subsidiary has formed a research collaboration with DaVita Labs to discover protein-based biomarkers that could be used to benefit dialysis patients.

The firms said that the primary focus of the collaboration will be on markers that predict vascular access failure.

DaVita Labs, a unit of DaVita HealthCare Partners, will provide specimens from its biorepository, while Myriad RBM will use its DiscoveryMAP platform to analyze the samples for potential use as biomarkers. Myriad expects to begin processing specimens for the collaboration in its fiscal year 2014, which begins July 1.

"We have extensive experience with research in kidney disease and inflammatory markers that we believe could increase the quality of care for dialysis patients," Craig Benson, president of Myriad RBM, said in a statement.

Financial and other terms of the agreement were not disclosed.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.